Belgian Trade Distributors Stock News

Solvay (ENXTBR:SOLB) just inked a supply agreement with Noveon Magnetics, setting the stage for delivery of rare earth oxides starting in 2026. This collaboration aims to create a sustainable supply chain for critical magnet materials in the context of ongoing supply challenges. See our latest analysis for Solvay. After a tough start to the year, Solvay’s share price has slipped 11.1% year-to-date, reflecting shifting investor sentiment despite big moves like the Noveon deal and steady...

Key Insights The projected fair value for Melexis is €54.64 based on 2 Stage Free Cash Flow to Equity With €55.65 share...

Anheuser-Busch InBev (ENXTBR:ABI) shares have climbed almost 5% over the past month, catching the interest of investors looking for momentum. The company’s improving financials add another factor for anyone watching food and beverage stocks right now. See our latest analysis for Anheuser-Busch InBev. Momentum appears to be building for Anheuser-Busch InBev, with the share price jumping more than 12% year-to-date and a 1-year total shareholder return of just over 4%. While recent financial...

KBC Group NV reported third quarter and nine-month earnings for the period ended September 30, 2025, with net income rising to €1.00 billion for the quarter and €2.57 billion for the nine months, both higher than the same periods last year. The company's earnings per share from continuing operations also increased over both periods, reflecting improved profitability and operational performance. We'll assess how the jump in net income and earnings per share informs KBC Group's ongoing...

Noveon Magnetics and Solvay recently announced a multi-year supply agreement for light and heavy rare earth oxides, with Solvay providing Neodymium-Praseodymium, Dysprosium, and Terbium oxides, sourced partly from recycled materials, to support Noveon's production of permanent magnets starting in 2026. This collaboration advances a more resilient and sustainable domestic supply chain for rare earth magnets amid ongoing global supply risks and growing demand. The agreement enhances Solvay's...

argenx SE recently received Health Canada approval for VYVGART SC as a monotherapy for adult patients with active chronic inflammatory demyelinating polyneuropathy (CIDP), making it the first innovative CIDP treatment option in Canada in over 30 years and the first FcRn blocker approved for this use. The once-weekly, subcutaneous self-administration of VYVGART SC presents a new level of flexibility and convenience for patients while potentially reducing demand for human-derived blood...

Campine NV ( EBR:CAMB ) shares have had a horrible month, losing 26% after a relatively good period beforehand. Of...

It's not a stretch to say that Azelis Group NV's ( EBR:AZE ) price-to-earnings (or "P/E") ratio of 14x right now seems...

On October 31, 2025, Cmb.Tech NV was removed from the Euronext 150 Index, an important benchmark for European equities. Such index exclusions can lead to substantial portfolio adjustments by institutional investors, as many funds track or benchmark to major indices. We'll explore how Cmb.Tech's index removal could reshape its investment narrative, especially given potential shifts in institutional ownership. We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next...

UCB (ENXTBR:UCB) received FDA approval for KYGEVVI, marking a major step in rare disease treatment. KYGEVVI is the first approved therapy for TK2d, a life-threatening mitochondrial disorder with very limited options. See our latest analysis for UCB. Following the FDA approval for KYGEVVI, UCB's momentum has been building. The share price has climbed nearly 20% year-to-date. After some short-term volatility, the stock's 1-year total shareholder return stands at an impressive 26%. Those who...

One way to deal with stock volatility is to ensure you have a properly diverse portfolio. Of course, the aim of the...

Montea Comm. VA (ENXTBR:MONT) just announced its earnings for the first nine months of 2025, showing higher sales compared to last year, but both net income and earnings per share declined. See our latest analysis for Montea Comm. VA. Despite Montea Comm. VA’s mixed nine-month results, investor sentiment has shown resilience, with the share price rising 12.2% year-to-date and the one-year total shareholder return reaching a solid 14.3%. While long-term three-year returns remain positive, the...

Syensqo reported third quarter 2025 earnings, revealing sales of €1.56 billion and net income of €39 million, compared to a third quarter net loss in 2024, despite a year-on-year decline in revenue for both the quarter and nine months ending September 30. The company’s rebound to profitability in the third quarter, following a loss a year earlier, underscores a shift in its performance trend even amid lower sales. We’ll assess how Syensqo’s return to quarterly profit, despite weaker sales,...

UCB announced that KYGEVVI, a combination therapy for thymidine kinase 2 deficiency (TK2d), has received approval from the U.S. FDA, making it the first and only approved treatment for this ultra-rare, life-threatening mitochondrial disorder in both adults and pediatric patients with symptom onset before age 12. This approval provides UCB with entry into a new therapeutic area with high unmet need, and comes with a Rare Pediatric Disease Priority Review Voucher from the FDA, highlighting...

Lotus Bakeries was recently added to the Euronext 150 Index, highlighting its growing profile among Europe’s largest listed companies. This milestone can influence share demand as index-tracking funds and institutional investors may adjust holdings to include the company. We’ll now explore how inclusion in a major index could impact Lotus Bakeries’ investment narrative and future institutional interest. AI is about to change healthcare. These 32 stocks are working on everything from early...

The Realco SA ( EBR:REAL ) share price has done very well over the last month, posting an excellent gain of 32%. The...

This week we saw the Banqup Group SA ( EBR:BANQ ) share price climb by 11%. But that doesn't change the fact that the...

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Montea Comm. VA recently reported earnings for the nine months ended September 30, 2025, with sales rising to €110.65 million from €89.71 million a year earlier and net income reaching €114.92 million, slightly lower than the prior year. Despite stronger sales, the company posted lower net income and basic earnings per share, highlighting pressures on profitability despite revenue growth. We'll explore how Montea Comm. VA's increased sales but contracting profit margins could shape the...

Anheuser-Busch InBev announced a US$6 billion share repurchase program and released its third quarter 2025 earnings, reporting sales of US$15.13 billion and net income of US$1.05 billion for the quarter ended September 30, 2025. The board also approved an interim dividend, renewed a key services framework with its Asia-Pacific subsidiary, and disclosed the upcoming departure of its longstanding Chief People Officer, marking a period of significant corporate actions. We'll explore how the...

NV Bekaert (ENXTBR:BEKB) has just been added to the Euronext 150 Index, catching the attention of the market. Inclusion in a major index often brings new opportunities from institutional and passive investors alike. See our latest analysis for NV Bekaert. Bekaert's inclusion in the Euronext 150 seems to have energized market sentiment, coinciding with a 2.12% one-day bump in the share price and capping off a 15.74% total shareholder return for the past year. The stock's longer-term track...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Key Insights Given the large stake in the stock by institutions, ageas' stock price might be vulnerable to their...